Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Scottish Medicines Consortium approves heart failure, breast and prostate cancer drugs

The Scottish Medicines Consortium (SMC) has published advice accepting three new medicines for frontline use by NHS Scotland.

The Scottish Medicines Consortium (SMC) has published advice accepting three new medicines for frontline use by NHS Scotland. The new drugs are eribulin (Halaven) for advanced breast cancer, sacubitril/valsartan (Entresto) for chronic heart failure and enzalutamide (Xtandi) for prostate cancer. However, the SMC was unable to accept nivolumab (Opdivo) for melanoma (skin cancer) and pertuzumab (Perjeta) for treatment of early stage breast cancer in patients before they receive surgery. Eribulin was accepted for the treatment of advanced breast cancer in those patients who have already received a number of treatments. It was considered under the SMC’s PACE (Patient and Clinician

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy